IONS — Ionis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $7.33bn
- $7.19bn
- $943.71m
AstraZeneca's Wainua fails key heart disease trial, shares tumble (updated)
AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial
Focus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Brief: Ionis Partner Biogen Announces Topline Results From Phase 2 Celia Study Of Diranersen
U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta
Ionis Q1 revenue rises 87% on R&D payments boost
Corrected: BRIEF-Ionis Pharmaceuticals Q1 Revenue USD 246 Million Vs. IBES Estimate USD 195.6 Million
Brief: Ionis Partner GSK Says FDA Grants Priority Review, Breakthrough Status to Hepatitis B Drug Bepirovirsen
Brief: Ionis Pharmaceuticals Inc - Zilganersen 50 Mg Meets Primary Endpoint, Stabilizes Gait Speed In Patients ≥5 Years At Week 61
U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop
U.S. RESEARCH ROUNDUP-Cars.Com, Dell, Zscaler
Brief: Olezarsen SNDA Accepted By The FDA For Priority Review
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara